Objective: To evaluate whether prophylactic chemotherapy (P-chem) with one bolus dose of actinomycin D (Act-D) during the uterine evacuation of patients with high-risk hydatidiform mole (Hr-HM) affects reproductive outcomes in subsequent pregnancies.

Methods: From 1987 to 2006, 1090 patients with gestational trophoblastic disease (GTD) were evaluated at a Trophoblastic Disease Center in southern Brazil; 265 with Hr-HM were selected and retrospectively analyzed. From 1996 to 2006, 163 received one bolus dose of Act-D at the time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-chem (Hr-HM-control group). In March 2009, the number of pregnancies, progression of first pregnancy, and association of low age and low parity with subsequent pregnancy were evaluated.

Results: The percentage of patients that became pregnant was similar in both groups (Hr-HM-control: 59.5%; Hr-HM-chem group: 45.7%; p=0.069) and independent of HM progression. Percentages of no pregnancies because of age (> or =40 years) or hysterectomy were also similar. Type of subsequent pregnancy was not statistically different between groups, and the rate of live births associated with pregnancies for which US showed a live fetus was high. Frequency of repeat GTD was unexpectedly high in both groups (4.2% and 6.3%; p=1.00).

Conclusions: P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.09.012DOI Listing

Publication Analysis

Top Keywords

bolus dose
12
uterine evacuation
12
subsequent pregnancy
12
patients high-risk
8
high-risk hydatidiform
8
hydatidiform mole
8
dose actinomycin
8
prophylactic chemotherapy
8
reproductive outcomes
8
trophoblastic disease
8

Similar Publications

Volume kinetic analysis of 2 crystalloid fluid bolus rates in anesthetized cats.

J Vet Emerg Crit Care (San Antonio)

January 2025

J. T. Vaughan Large Animal Teaching Hospital, Auburn University, Auburn, Alabama, USA.

Objective: To investigate the volume kinetic between 2 crystalloid fluid bolus rates in anesthetized cats.

Design: Prospective, randomized, dose-response study.

Setting: University laboratory.

View Article and Find Full Text PDF

Sweat gland cancers, particularly eccrine sweat gland carcinomas, are rare and challenging to treat due to their aggressive nature and inconspicuous clinical presentation. Aggressive digital papillary adenocarcinoma, a rare subtype, frequently presents with delays in diagnosis, increasing the risk of metastasis and recurrence. Surgical excision remains the standard treatment, but the role of postoperative radiation therapy is not well-established due to the paucity of data.

View Article and Find Full Text PDF

Background: Octreotide is commonly used to treat hypoglycemia due to sulfonylurea toxicity, but optimal dosing for this indication is not well defined.

Methods: We performed a systematic review to identify cases in the medical literature of octreotide use for sulfonylurea poisoning. Literature published on octreotide and sulfonylureas between octreotide's FDA approval on 10/21/1988 and 8/15/2024 was reviewed.

View Article and Find Full Text PDF

When a difficult airway is anticipated, awake tracheal intubation can be considered. Usually, low doses of sedatives are administered during this procedure for minimal sedation and anxiolysis, such as midazolam and remifentanil. The newly developed ultra-short-acting benzodiazepine remimazolam has a pharmacokinetic profile that is more suitable for titration during awake tracheal intubation than the long-acting midazolam.

View Article and Find Full Text PDF

Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.

World J Diabetes

January 2025

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.

Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).

Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!